Northland Securities Sticks to Their Buy Rating for Menlo Therapeutics (MNLO)


In a report released today, Tim Chiang from Northland Securities reiterated a Buy rating on Menlo Therapeutics (MNLO), with a price target of $3.50. The company’s shares closed last Friday at $2.24.

According to TipRanks.com, Chiang is a 2-star analyst with an average return of 0.2% and a 49.5% success rate. Chiang covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Pacira Pharmaceuticals, and BioDelivery.

Menlo Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $6.50, which is a 181.4% upside from current levels. In a report issued on May 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $2.50 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.48 and a one-year low of $1.00. Currently, Menlo Therapeutics has an average volume of 2.74M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.

Read More on MNLO:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts